HSD11B1 is upregulated synergistically by IFNγ and TNFα and mediates TSG-6 expression in human UC-MSCs. by Huang, Peiqing et al.
Huang et al. Cell Death Discovery            (2020) 6:24 
https://doi.org/10.1038/s41420-020-0262-7 Cell Death Discovery 
ART ICLE Open Ac ce s s
HSD11B1 is upregulated synergistically by IFNγ
and TNFα and mediates TSG-6 expression
in human UC-MSCs
Peiqing Huang 1, Yinghong Li1, Chenchang Xu1, Gerry Melino2,3, Changshun Shao 1 and Yufang Shi1,4,5
Abstract
Inflammatory factors such as IFNγ and TNFα could endow mesenchymal stem cells (MSCs) a potent
immunomodulatory property, a process called licensing, but the mechanisms are not fully understood. We here
found that glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1), which converts
inactive cortisone to the active cortisol and thereby regulates tissue glucocorticoid (GC) levels, was greatly
upregulated by IFNγ and TNFα in human umbilical cord-derived MSCs (UC-MSCs) in a synergistic manner. While IFNγ
alone was not able to induce HSD11B1, it could increase the activity of NF-kB and thus augment the upregulation of
HSD11B1 by TNFα. Interestingly, the upregulation of HSD11B1 by IFNγ and TNFα also required glucocorticoid
receptor. Furthermore, HSD11B1 was shown to be required for the expression of TNF-stimulated gene 6 (TSG-6), an
important anti-inflammatory effector molecule of MSCs. Therefore, the inflammatory factors IFNγ and TNFα can
promote GC metabolism and thereby drive the expression of anti-inflammatory factor TSG-6 in human UC-MSCs,
forming a potential negative feedback loop. These findings help to understand the relationship between
inflammation and GC metabolism.
Introduction
HSD11B1 (11β-hydroxysteroid dehydrogenase type 1), a
luminally oriented enzyme of the endoplasmic reticulum
membrane1, is wildly expressed in the body. It functions
to convert inactive cortisone to the active cortisol2.
Because endogenous glucocorticoid (GC) is indispensable
for maintaining homeostasis, HSD11B1 is also expected to
play a critical role in the modulation of metabolism and
inflammatory response. Indeed, some chronic inflamma-
tory conditions have been found to be associated with
increased HSD11B1 expression, such as atherosclerosis3,
inflammatory bowel disease, and colitis4,5. These obser-
vations are in line with many reports of induction of
HSD11B1 expression by proinflammatory cytokines in
various cell types6–8. In general, the regulation of
HSD11B1 expression by inflammatory factors appears to
be cell type-specifics. For instance, TNFα induce
HSD11B1 expression in human fibroblasts, but not in
human primary hepatocytes9,10. Therefore, the expression
and function of HSD11B1 remain to be further elucidated.
Various studies have demonstrated the exciting ther-
apeutic effect of MSCs in multiple sclerosis11, GvHD12,
fibrosis13, systemic lupus erythematosus (SLE)14, acute
lung injury15, inflammatory bowel diseases16. And there
are many ongoing Phase I–III clinical trials of MSCs in
treating inflammatory disease17. However, it should be
noted that MSCs are plastic in their immunomodula-
tion18. The immunosuppressive function of MSCs could
be reversed by GC when the two combined to aggravate
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inflammation in mice19, which reflects the complex
interaction between GC and MSCs.
Published investigations have shown that the therapeutic
effect of MSCs is mainly a result of immunomodulation
and that this function is licensed by inflammation12. A
cocktail of proinflammatory cytokines, IFNγ in combina-
tion with any of three other cytokines, TNFα, IL-1α, or IL-
1β, was shown to have the capability to induce the
immunosuppressive function of MSCs12. The licensed
MSCs were found to secrete several factors and metabo-
lites that mediate the anti-inflammatory effect of MSCs.
TSG-6, a hyaluronan-binding protein, is one of the
factors secreted by human MSCs. It can attenuate
inflammation and enhance tissue repair in mouse models
of acute lung injury15, peritonitis20, myocardial infarc-
tion21, corneal injury22, and arthritis23. However, despite
the well-recognized role of TSG-6 in immunomodulation,
the regulation of TSG-6 expression in human MSCs is not
very clear. We previously reported that while TNFα could
induce TSG-6 expression in human MSCs, the induction
could be substantially enhanced by another cytokine
IFNγ, via kynurenic acid, a metabolite of indoleamine 2,3-
dioxygenase (IDO)24.
In the present study, we found that HSD11B1 was
synergistically upregulated by IFNγ and TNFα in human
umbilical cord-derived MSCs (UC-MSCs). In this process,
IFNγ was found to promote the phosphorylation of p65, a
NF-κB subunit, and thus augment the HSD11B1 expres-
sion induced by TNFα. To our surprise, glucocorticoid
receptor (GR) was activated by IFNγ and TNFα and
mediated the upregulation of HSD11B1 by IFNγ and
TNFα. We also identified HSD11B1 to be an essential
molecule for the induction of anti-inflammatory TSG-6 by
IFNγ and TNFα. Our study reveals a novel link between
inflammatory factors, HSD11B1 and TSG-6 in human UC-
MSCs. This finding increases our understanding of the
regulation and function of HSD11B1 in inflammation, and
may contribute to optimization of MSCs-based clinical
treatments for inflammatory conditions.
Results
HSD11B1 was synergistically upregulated by IFNγ and
TNFα in human UC-MSCs
Previous reports have shown that the immunosuppres-
sive function of MSCs is induced by proinflammatory
cytokines, especially the combination of IFNγ and TNFα.
However, most of the previously identified anti-
inflammatory functions of MSCs are based on the secre-
tory effector molecules, such as TSG-6 and IGF-211.
Because GC is critically involved in the regulation of
inflammation, we set to explore the roles of GC meta-
bolism in MSCs. Several reports showed that HSD11B1,
the main enzyme that metabolizes GC, was upregulated in
human fibroblasts, chondrocytes, and adipocytes by
TNFα25. We therefore first examined the direct effect of
IFNγ and TNFα stimulation on HSD11B1 expression in
human UC-MSCs. We added recombinant human TNFα
and IFNγ each alone or in combination to the culture of
human UC-MSCs. TNFα induced the expression of
HSD11B1 (Fig. 1a, b), which is consistent with other
studies. Surprisingly, while IFNγ alone did not induce
HSD11B1, IFNγ, and TNFα in combination substantially
increased the expression of HSD11B1. These results
showed that IFNγ and TNFα could synergistically upre-
gulate the expression of HSD11B1 in human UC-MSCs.
NF-κB mediates the synergistic effects of IFNγ and TNFα on
HSD11B1 expression
Since TNFα mainly acts through NF-κB signaling in
regulating downstream genes pathway, we determined the
Fig. 1 The expression of HSD11B1 was significantly increased in IFNγ and TNFα licensed human UC-MSCs. a Real-time PCR was employed to
measure HSD11B1 in human UC-MSCs after TNFα and IFNγ stimulation. The histograms represent the mean values ± SEM from three independent
experiments (n= 9). Asterisks indicate highly significant (***p < 0.001) differences (Student’ t test). Data are presented as fold change relative to ctrl
human UC-MSCs. b Western blotting was performed to detect HSD11B1 in human UC-MSCs after TNFα and IFNγ stimulation.
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phosphorylation level of p65, a NF-κB subunit, in human
UC-MSCs in the presence of TNFα and IFNγ each alone
or in combination. We observed that either of the two
cytokines could increase the level of p-p65, but the
combination resulted in the highest p65 phosphorylation
level (Fig. 2a).
To determine the role of p65 in HSD11B1 regulation,
we examined the effect of BAY 11-7082, an NF-κB inhi-
bitor, on HSD11B1 expression in IFNγ and TNFα -treated
human UC-MSCs. The results showed that the upregu-
lation of HSD11B1 by the cytokines was nearly abolished
when NF-κB activity was inhibited (Fig. 2b, c). To further
investigate this phenomenon, we knocked down p65 in
human UC-MSCs by siRNA, and found that the expres-
sion of HSD11B1 was suppressed after p65 depletion
(Fig. 2d, e). These results indicate that the upregulation of
HSD11B1 by IFNγ and TNFα was achieved through
NF-κB signaling.
GR was required for the upregulation of HSD11B1 by IFNγ
and TNFα
It was well established that GCs can upregulate
HSD11B1 expression in a variety of cells by activating GR.
In addition, phosphorylation at the Ser211 site was
reported to be a marker of GR activation26. To test
whether GR is involved in the upregulation of HSD11B1
by the two cytokines, we examined the phosphorylation
level of GR in human UC-MSCs exposed to IFNγ and
TNFα stimulation. We found that the level of phos-
phorylated GR at Ser211 was significantly higher in the
cytokines-treated cells than in control (Fig. 3a).
To further explore the role of GR in IFNγ and TNFα-
induced HSD11B1 expression, we knocked down GR in
human UC-MSCs by transfection with siRNA. Interest-
ingly, after GR depletion, the upregulation of HSD11B1 by
IFNγ and TNFα was weakened (Fig. 3b, c), suggesting that
GR is involved in the regulation of HSD11B1 by IFNγ and
TNFα.
We next treated human UC-MSCs with RU486, a GC
competitive GR inhibitor. As expected, RU486 greatly
inhibited the induction of HSD11B1 by dexamethasone
(Dex) (Fig. 3d, e). However, to our surprise, RU486 was
found to promote the expression of HSD11B1 induced by
IFNγ and TNFα at both mRNA and protein levels (Fig. 3f,
g). At the same time, level of p-GR(Ser211) increased.
While RU486 inhibited the p-GR(Ser211) induced by Dex
Fig. 2 IFNγ and TNFα synergistically enhanced the expression of HSD11B1 in human UC-MSCs via NF-κB p65. a Western blotting was
performed to detect p-p65 (Ser536) in human UC-MSCs after TNFα and IFNγ stimulation. b Real-time PCR was employed to measure HSD11B1 in
human UC-MSCs when NF-κB was inhibited by BAY 11-7082 in IT (TNFα combined with IFNγ) stimulation. The histograms represent the mean values
± SEM from three independent experiments (n= 9). Asterisks indicate highly significant (***p < 0.001) differences (ANOVA). Data are presented as fold
change relative to DMSO-ctrl human UC-MSCs. c Western blotting was performed to detect HSD11B1 in human UC-MSCs when NF-κB was inhibited
by BAY 11-7082 in IT stimulation. d Knockdown efficiency of sip65 was examined by Western blotting. Real-time PCR was employed to measure
HSD11B1 in p65-depleted human UC-MSCs after IT stimulation. The histograms represent the mean values ± SEM from three independent
experiments (n= 9). Asterisks indicate highly significant (***p < 0.001) differences (ANOVA). Data are presented as fold change relative to siCTRL-ctrl
human UC-MSCs. e Western blotting was performed to detect HSD11B1 in p65-depleted human UC-MSCs after IT stimulation.
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(Fig. 3e), it increased the level of p-GR(Ser211) induced by
IFNγ and TNFα (Fig. 3g). These results indicated that
while RU486 can competitively inhibit the effect of Dex, it
does not impair the function of GR in promoting
HSD11B1 expression in the context of IFNγ and TNFα-
treated human UC-MSCs. This result suggest that GR
probably played a structural role in IFNγ and TNFα-
licensed human UC-MSCs. Future studies are required to
determine whether GR functions to coordinate the
binding of NF-kB and other transcription factors to
HSD11B1 promoter.
HSD11B1 is required for the induction of TSG-6 by IFNγ
and TNFα
Like that of HSD11B1, the expression of TSG-6, an
important immunoregulatory molecule, was significantly
increased when stimulated by IFNγ and TNFα (Fig. 4a).
We next tested whether there is link between HSD11B1
and TSG-6 by depleting HSD11B1 in human UC-MSCs.
Interestingly, the expression of TSG-6 was greatly
reduced after HSD11B1 depletion in IFNγ and TNFα-
licensed human UC-MSCs (Fig. 4b), which strongly sug-
gested that HSD11B1 was involved in the upregulation of
TSG-6 by IFNγ and TNFα.
TSG-6 was identified as a transcriptional target of NF-
κB27. As expected, the expression of TSG-6 in human UC-
MSCs was downregulated when treated with NF-κB
inhibitor, BAY 11-7082 (Fig. 4c). Furthermore, the phos-
phorylation of p65 in HSD11B1-depleted human UC-
MSCs was decreased (Fig. 4d), which indicates that
HSD11B1 may contribute to the maintenance of
p65 signal pathway. Taken together, the data suggested
that HSD11B1 might mediate the expression of TSG-6
through NF-κB.
Discussion
The MSCs-based treatment of inflammatory diseases is
being widely tested in preclinical and clinical studies.
Because of their powerful anti-inflammatory property, it is
safe to predict that MSCs therapy will be a potential
treatment for diseases such as SARS and the current
COVID-19, or novel coronavirus pneumonia, in which
the damage caused by cytokine storms is hard to control.
Previous studies had demonstrated that the immuno-
suppressive ability of MSCs is not innate, but, is induced
by the proinflammatory cytokines, like IFNγ in combi-
nation with TNFα12. Thus, ironically, proinflammatory
cytokines can lead to immunosuppression under certain
Fig. 3 Glucocorticoid receptor (GR) was involved in IFNγ and TNFα-induced HSD11B1 expression. a Western blot analysis was performed to
detect p-GR(Ser211) in human UC-MSCs under IT (TNFα combined with IFNγ) stimulation. b Knockdown efficiency of GR was examined by Western
blotting. Real-time PCR was employed to measure HSD11B1 in GR-depleted human UC-MSCs after IT stimulation. The histograms represent the mean
values ± SEM from three independent experiments (n= 9). Asterisks indicate highly significant (***p < 0.001) differences (ANOVA). Data are presented
as fold change relative to siCTRL-ctrl human UC-MSCs. c HSD11B1 was detected in GR-depleted human UC-MSCs after IT stimulation by Western
blotting. d Real-time PCR was performed to detect HSD11B1 in human UC-MSCs under stimulation of dexamethasone or RU486 alone or a
combination of them. The histograms represent the mean values ± SEM from three independent experiments (n= 9). Asterisks indicate highly
significant (***p < 0.001) differences (ANOVA). Data are presented as fold change relative to DMSO-ctrl human UC-MSCs. e Western blotting was
employed to detect HSD11B1 and p-GR(Ser211) in human UC-MSCs under stimulation of dexamethasone or RU486 alone or a combination of them.
f Real-time PCR was employed to measure HSD11B1 in human UC-MSCs under stimulation of RU486 alone or a combination of IT. The histograms
represent the mean values ± SEM from three independent experiments (n= 9). Asterisks indicate highly significant (**p < 0.01) differences (ANOVA).
Data are presented as fold change relative to DMSO-ctrl human UC-MSCs. g Western blotting was employed to detect HSD11B1 and p-GR(Ser211) in
human UC-MSCs under stimulation of RU486 alone or a combination of IT.
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circumstances12. In human UC-MSCs, these cytokines
induce a dramatic upregulation in HSD11B1, an impor-
tant enzyme that metabolizes and activates GC, which
may enhance local anti-inflammatory effects of GC.
Stimulation of HSD11B1 activity following TNFα
exposure has been described in early progenitor cells of
the mesenchymal lineage and differentiated cells such as
osteoblasts and adipocytes, particularly in cells of human
origin26,28,29. These studies concluded that HSD11B1
induction by TNFα may enhance local GC generation and
function. The regulation of HSD11B1 expression by IFNγ
is less understood, although. IFNγ was reported to inhibit
HSD11B1 expression in monocytes30. To our surprise, we
observed that while IFNγ alone was unable to induce
HSD11B1, it synergistically increased the expression of
HSD11B1 when combined with TNFα. Our results thus
revealed that the upregulation of HSD11B1 is exerted
through the concerted action of TNFα and IFNγ in
human UC-MSCs.
NF-κB was reported to positively regulate HSD11B1
expression in human synovial fibroblasts and human
dermal fibroblasts31 and in adipocytes of diet-induced
obese mice32. However, it was also shown to inhibit the
expression of HSD11B1 in mouse skeletal muscle cells33.
Our results with human UC-MSCs are consistent with
those obtained with fibroblasts and adipocytes, which are
presumably derived from MSCs. It should be noted that
C/EBPα and C/EBPβ also serve as positive regulators of
HSD11B1 P1 promoter regulator34. It is therefore rea-
sonable to speculate that C/EBP may be involved in
HSD11B1 regulation by IFNγ and TNFα. Further studies
may reveal more species-, tissue- and context-specific
factors in the regulation of HSD11B1.
GC is well documented to stimulate HSD11B1 expres-
sion and activity in most cell types. Consistently,
HSD11B1 was found to be greatly upregulated by dex-
amethasone in human UC-MSCs, and this effect was
abolished when RU486, a GC competitive GR inhibitor,
was applied. Surprisingly, the HSD11B1 upregulation by
IFNγ and TNFα was even further increased by RU486. In
contrast, GR depletion led to a suppression of HSD11B1
in the same context. These seemingly contradictory
results could be due to differential consequences of
RU486 treatment and GR depletion. RU486 binding to
Fig. 4 HSD11B1 mediated the expression of TSG-6 induced by IFNγ and TNFα via NF-κB. a TSG-6 in human UC-MSCs under IT (TNFα combined
with IFNγ) stimulation was detected by real-time PCR. The histograms represent the mean values ± SEM from three independent experiments (n= 9).
Asterisks indicate highly significant (***p < 0.001) differences (Student’ t test). Data are presented as fold change relative to ctrl human UC-MSCs.
b Knockdown efficiency of siHSD11B1 was examined by Western blotting. TSG-6 in HSD11B1-depleted human UC-MSCs after IT stimulation was
measured by real-time PCR. The histograms represent the mean values ± SEM from three independent experiments (n= 9). Asterisks indicate highly
significant (**p < 0.01) differences (Student’ t test). Data are presented as fold change relative to siCTRL human UC-MSCs. c TSG-6 in human UC-MSCs
under BAY 11-7082 and IT stimulation was analyzed by real-time PCR. The histograms represent the mean values ± SEM from three independent
experiments (n= 9). Asterisks indicate highly significant (***p < 0.001) differences (ANOVA). Data are presented as fold change relative to DMSO-ctrl
human UC-MSCs. d p-p65(Ser536) in HSD11B1-depleted human UC-MSCs under IT stimulation was detected by Western blotting. e The schematic
overview of IFNγ and TNFα regulated HSD11B1 production and HSD11B1 regulated TSG-6 production in human UC-MSCs.
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GR may induce some conformational change of GR and
further activate it. Indeed, the phosphorylation of GR at
the Ser211, a marker of GR activation, was enhanced by
RU486, which might lead to augmented HSD11B1
expression. These data collectively suggest that GR may
play a structural role in the upregulation of HSD11B1 by
IFNγ and TNFα.
We found that the upregulation of HSD11B1 by the
inflammatory factors in human UC-MSCs contributes to
their anti-inflammatory function. Depletion of HSD11B1
dramatically reduced the expression of TSG-6, suggesting
that HSD11B1 is required for MSCs to acquire some of
their anti-inflammatory properties.
Previous studies suggested that increasing HSD11B1
expression is a mechanism to initiate the process of
inflammatory resolution through increased local GC
generation in IL1β and lipopolysaccharide stimulation35.
However, blocking GC binding to GR did not decrease the
expression of TSG-6 induced by TNFα and IFNγ stimu-
lation (data not show), which suggested that HSD11B1
could upregulated TSG-6 independent of GC. We con-
firmed TSG-6 as a target gene of NF-κB in human UC-
MSCs. Furthermore, we noticed that the activity of NF-κB
was repressed in HSD11B1-depleted MSCs. These results
suggested that HSD11B1 mediated the induction of TSG-
6 through NF-κB (Fig. 4e). The feedforward loop between
NF-κB and HSD11B1 may augment the immunosup-
pressive function of MSCs under inflammatory
conditions.
In conclusion, we demonstrated a critical role for GC
metabolism in the acquisition of the immunosuppressive
capability by human UC-MSCs exposed to proin-
flammatory cytokines. These findings may allow the bet-
ter clinical utilization of MSCs.
Materials and methods
Isolation, expansion, and cultivation of human UC-MSCs
The human umbilical cord was obtained from the First
Affiliated Hospital of Soochow University with the
informed consent of the donor and approved for use by
the ethical standards of the Ethics Committee of both
Soochow University and the First Affiliated Hospital of
Soochow University.
Human UC-MSCs were obtained from human umbili-
cal cord using a previously described protocol15. Briefly,
the umbilical cord was stored in sterilized glass bottles
containing phosphate-buffered saline (PBS) for processing
within 4 h. Then the umbilical cord was washed with PBS
to remove blood, and then minced and seeded into cell
culture dishes with low-glucose DMEM (HyClone, Neb,
USA)-containing 10% fetal bovine serum (FBS) (Gibco,
MA, USA), penicillin/streptomycin (10 units) (Thermo
Fisher Scientific, MA, USA), and were incubated at 37 °C
in 5% CO2 atmosphere. The medium was replaced for
every 48 h with fresh medium. Upon reaching 80–90%
confluency, cells were harvested using trypsin-EDTA and
then used for experiments immediately or frozen and
stored in liquid nitrogen. Human UC-MSCs were iden-
tified by the specific cell surface markers, including HLA-
DR (−), CD45 (−), CD31 (−), CD34 (−), CD105 (+),
CD29 (+), CD90 (+), CD73 (+), and CD44 (+). These
MSCs were capable of differentiating into osteocytes and
adipocytes under the respective differentiation conditions.
Human UC-MSCs were maintained in low-glucose
DMEM (HyClone, USA), supplemented with FBS (10%)
(Gibco, USA), penicillin/streptomycin (10 units) (Thermo
Fisher, USA), 10 ng/ml human-bFGF (R&D, USA) and
incubated at 37 °C in the presence of 5% CO2. The media
were replaced for every 72 h and the cells were split twice
a week. All cells were regularly tested to ensure they were
mycoplasma-free. Cells were used before the 12th
passage.
Treatments of human UC-MSCs
Human UC-MSCs were cultured in 12-well plates, upon
reaching 80–90% confluency, cells were washed with PBS
and then treated with indicated stimulations. The stimu-
lations were TNFα (eBioscience, MA, USA) or IFNγ
(eBioscience, USA) alone or a combination of these two
cytokines (10 ng/ml each) for 24 h; TNFα (10 ng/ml) and
IFNγ (10 ng/ml) combined with BAY 11-7082 (5 μM)
(Selleck, WA, USA) or DMSO (Sigma, MA, USA) for 24 h;
TNFα (10 ng/ml) and IFNγ (10 ng/ml) combined with
RU486 (3 μM) (Selleck, USA) or DMSO for 24 h; Dex-
amethasone (10 ng/ml) (Sigma, USA) combined with
RU486 (3 μM) or DMSO for 24 h.
Real-time PCR
Total RNA was extracted from cell lysates according to
the manufacturer’s instructions using Trizol reagent
(Thermo Fisher Scientific, USA). First-strand cDNA
synthesis was performed using PrimeScript™ RT Master
Mix (TaKaRa Biotech, Dalian, China) according to the
manufacturer’s instructions. The total reaction volume of
10 μL was comprised of 1 ng cDNA, 3 μL DNAase/
RNAse-free water (TaKaRa Biotech, China), 1 μL primers
(GENEWIZ, Suzhou, China), 5 μL SYBR qPCR SuperMix
plus (with ROX) (Novoprotein, Shanghai, China). After
pipetting the reaction mixture into a 384-well plate, real-
time PCR was running by QuantStudio 6 Flex (Applied
Biosystems, MA, USA). mRNA levels were calculated
referring to β-actin as a housekeeping gene. To compare
the expression of each gene in the different treatment
conditions, the fold change of expression was calculated
using the equation 2−ΔΔCt where ΔΔCt=ΔCt (treated)−
ΔCt (control), ΔCt (treated)= [Ct (target gene)−Ct
(β-actin)], ΔCt (control)= [Ct (target gene)−Ct
(β-actin)]. Real-time PCR was performed using the
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CAGACCG-3′. The total amount of mRNA was normal-
ized to endogenous β-actin mRNA.
Western blotting
Total cellular proteins were extracted by RIPA buffer
(Beyotime, Shanghai, China) containing PMSF (Beyotime,
China) and phosphatase inhibitors (Roche, NJ, USA).
Protein samples were separated on a 10% sodium dodecyl
sulfate-polyacrylamide gel, and separated proteins were
electroblotted onto polyvinylidene difluoride membranes.
The membranes were blocked for 2 h with tris-buffered
saline containing Tween 20 (TBST) with 5% albumin
bovine serum (Amresco, OH, USA) at room temperature
with gentle shaking. Then incubated the membranes with
primary antibodies HSD11B1 (ab39364, abcam, MA,
USA), tubulin (2128S, Cell Signaling Technology, MA,
USA), p-p65 (Ser536) (3033S, Cell Signaling Technology,
USA), p65 (8242S, Cell Signaling Technology, USA), p-
GR (Ser211) (4161S, Cell Signaling Technology, USA), or
GR (12041S, Cell Signaling Technology, USA) for 10 h at
4 °C with gently shaking. After washing 3 times with
TBST for 5 min each, the membranes were incubated
with horse radish peroxidase-conjugated rabbit secondary
antibodies (7074S, Cell Signaling Technology, USA) for
1 h at room temperature with gentle shaking. After
incubation, membranes were harvested with NcmECL
Ultra Kit (NCM biotech, Suzhou, China) according to the
manufacturer’s instructions and the signal was detected
by Ultra-sensitive automatic imaging analysis system
(ProteinSimple, CA, USA). Tubulin was used as an
internal control.
Transfections with siRNA
Human UC-MSCs were plated on 12-well plate at the
density of 50% per well and were treated with 1 µl
INTERFERin® reagent (PolyPlus-transfection, Illkirch,
France) along with 1 μl GR, p65 or HSD11B1 siRNA
(GenePharma, Shanghai, China). The same amount of
control siRNA (GenePharma, China) was also transfected
into MSCs as control according to the manufacturer’s
protocols. After 48 h, cells were washed twice with PBS,
and then cells were treated with indicated stimulations.
The efficiency of transection was monitored by Western
blotting. p65 siRNA sequences were 5′-CCCUAUCCC
UUUACGUCAUTT-3′ and 5′-AUGACGUAAAGGGA
UAGGGTT-3′. GR siRNA sequences were 5′-GAUG
UAAGCUCUCCUCCAUTT-3′ and 5′-AUGGAGGAG
AGCUUACAUCTT-3′. HSD11B1 siRNA sequences were
5′-GCAGGAAGAUCCUGGAAUUTT-3′ and 5′-AAUUC
CAGGAUCUUCCUGCTT-3′. Control siRNA sequences
were 5′-UUCUCCGAACGUGUCACGUTT-3′ and 5′-AC
GUGACACGUUCGGAGAATT-3′.
Statistical analysis
Each experiment was performed in biological triplicate
each time and repeated independently at least three
times. The data are presented as mean ± standard error of
the mean. Statistical significance was analyzed using
Student’s t test, analysis of variance test calculation using
GraphPad Prism 8 (GraphPad Software Inc., CA, USA),
p values < 0.05 were considered statistically significant.
p < 0.05 is denoted as *, p < 0.01 as **, p < 0.001 as ***, p <
0.0001 as ****.
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